Timolol

Treats elevated intraocular pressure. Sold as Betimol. Every FDA application for this active ingredient: 1 branded and 2 generic.

As of Nov 13, 2026, FDA lists 3 applications for Timolol (sold as Betimol), first approved Mar 31, 1995, with 0 new uses approved and 0 published complete response letters.

First approved: Mar 31, 1995
Applications: 3
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $3.2M

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2025	Change	Beneficiaries
Timolol	Part D	$2.0M	New	5,499
Betimol	Part D	$674K	-81%	1,773
Istalol	Part D	$485K	-26%	272

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Mar 31, 1995	BetimolNDA 20439 · New active ingredient	Thea Pharma	9	Marketed
Sep 30, 2016	TimololANDA 205309	Epic Pharma LLC	0	Discontinued
Oct 10, 2024	TimololANDA 216654	Somerset	0	Marketed

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number. Drugs@FDA